This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Aqeel Fatmi Appointed Executive Vice President, Global Research & Development And Chief Scientific Officer

TORONTO, Jan. 9, 2013 /PRNewswire/ - Patheon Inc. (TSX: PTI), a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry, today announced that Aqeel Fatmi, Ph.D., was appointed as Executive Vice President, Global Research & Development of the proprietary products and technology business as well as Patheon's Chief Scientific Officer.

"I am extremely pleased to be formally welcoming Aqeel to Patheon's executive team, as his expertise and leadership within the industry is truly remarkable" stated James C. Mullen, Patheon's Chief Executive Officer.  "In his new role, Aqeel will be focused on supporting the advancement of Patheon's recently acquired business unit focused solely on proprietary products and technology."

"I am excited about the opportunity to move forward with the newly combined company," commented Dr. Fatmi.  "It has been an honor to be a part of growing Banner's business over the last several years and I look forward to playing a further role in developing the new vision and strategy for the business."

Dr. Fatmi most recently served on Banner Pharmacaps' global leadership team as Global Vice President, Research & Development and Operations.  In this role, he managed the development, registration, tech transfer and launch of new and existing proprietary and customer products, as well as the oversight of all of the company's production operations. Dr. Fatmi was a founder of the Georgia Combinatorial Chemistry Center at Georgia State University in Atlanta with a focus to discover small molecule drugs for cancer, HIV and other infectious diseases. He spent a major part of his career at Solvay Pharmaceuticals, where he served as Senior Vice President of Research & Development, being responsible for the development, approval and launch of new drugs.

Dr. Fatmi holds a Ph.D. in Medicinal Chemistry from The University of Georgia, Athens. After graduation Dr. Fatmi was a National Science Foundation Post Doctoral Fellow for one year at The University of Georgia.

About Patheon Inc.

Patheon Inc. (TSX: PTI) is a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry for a full array of solid and sterile dosage forms.  Through the company's recent acquisition of Banner Pharmacaps - a market leader in soft gelatin capsule technology - Patheon now also includes a proprietary products and technology business.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs